Recent advances in rilpivirine: New data and promising treatment option

AIDS Reviews

Volumn 16, Issue 3, 2014, Pages 172-181

  Casado, José Luis ^a   Bañón, Sara ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Abacavir lamivudine; Antiretroviral; HIV; Rilpivirine; Switching

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; CHOLESTEROL; CYTOCHROME P450 3A4; DACLATASVIR; DARUNAVIR; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LEDIPASVIR; LIPID; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; TENOFOVIR DISOPROXIL; TRIACYLGLYCEROL; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR; NITRILE; PYRIMIDINE DERIVATIVE;

AREA UNDER THE CURVE; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; GENE MUTATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTRANSAMINASEMIA; LIPID METABOLISM; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; MIXED INFECTION; NONHUMAN; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; VIRUS RESISTANCE; COMPLICATION; DISEASE CARRIER; DRUG COMBINATION; HIV INFECTIONS;

DIDEOXYNUCLEOSIDES; DISEASE RESERVOIRS; DRUG THERAPY, COMBINATION; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; NITRILES; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84907569083     PISSN: 11396121     EISSN: 16986997     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Hogg R, Lima V, Sterne J, et al; Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-9.
2. Garvey L, Winston A. Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs. 2009;18:1035-41.
3. James C, Preininger L, Sweet M. Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor. Am J Health Syst Pharm. 2012;69:857-61.
4. Miller C, Crain J, Tran B, Patel N. Rilpivirine: a new addition to the anti-HIV-1 armamentarium. Drugs Today (Barc). 2011;47:5-15.
5. Cohen C, Molina J, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr. 2012;60:33-42.
6. Cohen C, Molina J, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS. 2013;27:939-50.
7. Rimsky L, Van Eygen V, Hoogstoel A, et al. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials. Antivir Ther. 2013;18:967-77.
8. Cohen C, Wohl D, Arribas J, et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS. 2014;28:989-97.
9. Nelson M, Amaya G, Clumeck N, et al. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother. 2012;67:2020-8.
10. Lyseng-Williamson KA, Scott LJ. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection. Clin Drug Investig. 2012;32:715-22.
11. Ryom L, Mocroft A, Kirk O, et al. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS. 2014;28:187-99.
12. Zaharatos G, Wainberg M. Update on rilpivirine: a new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication. Ann Med. 2013;45:236-41.
13. Cohen C, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378:229-37
14. Tebas P, Sension M, Arribas J, et al. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-infected adults treated with rilpivirine or efavirenz over 96 weeks in the ECHO and THRIVE Trials. Clin Infect Dis. 2014;59:425-34.
15. Marshall N, Hedley L, Smith C, et al. Is switching to Kivexa with rilpivirine as effective as switching to Eviplera in clinical practice? HIV Med. 2014;15(Suppl 3):117.
16. Casado J, Moreno S. [Potential role of rilpivirine in simplification regimens]. Enferm Infecc Microbiol Clin. 2013;31(Suppl 2):30-5.
17. Palella F, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014;28:335-44.
18. Lambert-Niclot S, Charpentier C, Storto A, et al. Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy. J Antimicrob Chemother. 2014;69:1086-9.
19. Crauwels H, Vingerhoets J, Ryan R, Witek J, Anderson D. Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects. Antivir Ther. 2012;17:439-46.
20. Mills A, Cohen C, Dejesus E, et al. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. HIV Clin Trials. 2013;14:216-23.
21. Ward D, Grant R. Rilpivirine/tenofovir/emtricitabine fixed-dose combination is an efficacious and well-tolerated "switch" regimen for patients on therapy. J Int AIDS Soc. 2012;15:18351.
22. Rokx C, Verbon A, Rijnders B. Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy. HIV Med. 2014. [Epub ahead of print].
23. Cevik M, Sonecha S, Nelson M. Safety and efficacy of fixed-dose combination rilpivirine-tenofovir-emtricitabine (RPV/TDF/FTC) in treatmentexperienced patients infected with HIV-1. J Int AIDS Soc. 2012;15:18291.
24. Allavena C, Dailly E, Reliquet V, et al. Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects. J Antimicrob Chemother. 2014. [Epub ahead of print].
25. Mora-Peris B, Watson V, Vera J, et al. Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. J Antimicrob Chemother. 2014;69:1642-7.
26. Pozniak A, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24:55-65.
27. Diaz-Delfin J, Domingo P, Mateo M, et al. Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antimicrob Agents Chemother. 2012;56:3369-75.
28. Casado J. Liver toxicity in HIV-infected patients receiving novel secondgeneration nonnucleoside reverse transcriptase inhibitors etravirine and rilpivirine. AIDS Rev. 2013;15:139-45.
29. Wilkin A, Pozniak A, Morales-Ramirez J, et al. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses. 2012;28:437-46.
30. van Heeswijk R, Beumont M, Kauffman R, Garg V. Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther. 2013;18:553-60.
31. Ouwerkerk-Mahadevan S, Sekar V, Simion A, Peeters M, Beumont-Mauviel M. The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers. 50th Infectious Disease Society of America Annual Meeting, Oct 17-21, San Diego, USA, 2012.
32. Crauwels H, van Heeswijk R, Stevens M, et al. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013;15:87-101.
33. Hodder S, Arasteh K, De Wet J, et al. Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13:406-15.
34. Ryan R, Dayaram Y, Schaible D, Coate B, Anderson D. Outcomes in older versus younger patients over 96 weeks in HIV-1-infected patients treated with rilpivirine or efavirenz in ECHO and THRIVE. Curr HIV Res. 2013;11:570-5.
35. Creticos C, McDonald C, Segal-Maurer S, et al. STaR: Single-tablet regimen rilpivirine/emtricitabine/tenofovir DF is safe and well-tolerated with efficacy comparable to efavirenz/emtricitabine/tenofovir DF in ARTnaïve females at Week 96. 4th International Workshop on HIV and Women, from Adolescence through Menopause January 13-14, 2014. Washington DC, USA. [Abstract 16].
36. Brown KC, Paul S, Kashuba AD. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet 2009,48:211-241.
37. Jackson A, Else L, Higgs C, et al. Rilpivirine with darunavir/ritonavir: Pharmacokinetics & safety in HIV therapy-naïve patients. CROI, Boston, March 2014. [Abstract 507].
38. Ford S, Gould E, Chen S, et al. Lack of pharmacokinetic (PK) interaction between rilpivirine and the integrase inhibitors dolutegravir and S/GSK1265744. 52nd ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy, September 9-12, San Francisco, 2012.